Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03571321
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- NCT03571321 ↗
- Recruiting
- University of Chicago
- Focused
We haven't built an HCP commentary report on NCT03571321 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03571321 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Acute Lymphoblastic Leukemia; ALL, Childhood; ALL
- Interventions
- Ruxolitinib; Cyclophosphamide; Cytarabine; Mercaptopurine; Vincristine; Pegaspargase; Rituximab; Methotrexate (Intrathecal Administration); Methotrexate (Intravenous Administration); Dexamethasone; Doxorubicin; Thioguanine; Methotrexate Oral Product
- Arms
- Ruxolitinib · Experimental
- Enrollment
- 15 (estimated)
- Primary outcomes
- Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given
- Sponsor
- University of Chicago with Incyte Corporation
- Start
- May 28, 2019
- Primary completion
- Sep 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03571321 · updated Jun 29, 2026